We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Olympus

Manufactures optical and digital equipment for the healthcare and consumer electronics sectors, including endoscopy a... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Immunohistochemistry Biomarkers Used to Subtype Gastric Intestinal Metaplasia

By LabMedica International staff writers
Posted on 04 May 2022
Print article
Image: The Vectra 3 System for Quantitative Pathology Imaging (Photo courtesy of PerkinElmer)
Image: The Vectra 3 System for Quantitative Pathology Imaging (Photo courtesy of PerkinElmer)

Gastric cancer (GC) is the fifth most common and third most lethal cancer globally. Patients with GC are often asymptomatic, with presentation occurring at advanced stage, and a low 5-year survival rate in most countries. Intestinal metaplasia is considered a key pivot point in the Correa model of GC.

The Correa model describes histologically defined conditions initiated by Helicobacter pylori infection, from chronic gastritis (ChG) to atrophic gastritis, intestinal metaplasia (IM), dysplasia and finally to the intestinal type of GC. Successful H. pylori eradication treatment in the early stages of this cascade can reverse the process, but in a subset of IM patients, eradication does not prevent them from progressing to GC suggesting that IM is a key point in gastric carcinogenesis.

Gastroenterologists at the Royal Melbourne Hospital (Melbourne, Australia) and their colleagues selected CD10 and Das1 as candidate biomarkers to distinguish complete and incomplete IM glands in tissues from patients without GC (IM-GC) and patients with GC (IM + GC). H&E stained gastric IM tissue samples collected post-endoscopy/gastrectomy were subtyped at the time of collection by the in-house pathologist. Individual IM glands were subtyped as complete or incomplete with principal criteria being the presence of a brush border and gland morphology.

Immunohistochemistry (IHC) was performed on sequential 4 μm formalin-fixed, paraffin-embedded (FFPE) sections. Anti-CD10 staining was carried out using both single IHC and as part of a multiplex IHC panel. Multiplexed IHC stained sections were scanned and visualized on a VECTRA imaging system (Canfield Scientific, Parsippany, NJ, USA). Das1 staining was performed with overnight incubation of the primary antibody and slides were scanned on a VS120 slide scanner microscope and imaged using cellSens Dimension software (Olympus, Tokyo, Japan).

The scientists reported that across both cohorts CD10 stained the IM brush border and was shown to have a high sensitivity (87.5% and 94.9% in IM-GC and IM + GC patients respectively) and specificity (100.0% and 96.7% respectively). By contrast Das1 stained mainly goblet cells and the apical membrane of epithelial cells, mostly of incomplete IM glands with a low sensitivity (28.6% and 29.3% in IM-GC and IM + GC patients respectively) but high specificity (98.3% and 85.1% respectively). Whole tissue digital quantification of Das1 staining showed a significant association with incomplete IM compared to complete IM, both in IM-GC and in IM + GC patients. Additionally, complete IM in IM + GC patients exhibited significantly more Das1 staining than in IM-GC patients.

The authors concluded that overall CD10 was shown to be an outstanding biomarker for complete IM and Das1 was shown to have potential as an additional risk-associated biomarker when used in combination with digital imaging quantification. Their clinical use could lead to better patient stratification with improved targeted surveillance of IM patients, ultimately leading to prevention or early detection of GC. The study was published on April 21, 2022 in the journal BMC Gastroenterology.

Related Links:
The Royal Melbourne Hospital
Canfield Scientific
Olympus 

New
Gold Supplier
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
New
Data Management Software
DataSite
New
Influenza A+B Test
Anyplex FluA/B Typing Real-Time Detection
New
Automated Immunoassay Analyzer
cobas e 411

Print article
IIR Middle East

Channels

Molecular Diagnostics

view channel
Image: Metabolomic profiling reveals risk of multiple diseases all at once (Photo courtesy of BIH)

Single Blood Test Predicts Risk of Multiple Diseases Simultaneously Using AI

Prevention is better than cure. To prevent diseases from occurring in the first place, it is important to identify those individuals who are at particularly high risk as early as possible.... Read more

Technology

view channel
Image: OneDraw Blood Collection Device significantly reduces obstacles for drawing blood (Photo courtesy of Drawbridge Health)

Near Pain-Free Blood Collection Technology Enables High-Quality Testing

Blood tests help doctors diagnose diseases and conditions such as cancer, diabetes, anemia, and coronary heart disease, as well as evaluate organ functionality. They can also be used to identify disease... Read more

Industry

view channel
Image: The MC-80 digital cell morphology analyzer can screen and diagnose malignant and non-malignant blood diseases (Photo courtesy of Mindray)

Mindray Showcases Hematology Innovations at ISLH 2022

Mindray (Shenzhen, China) showcased its hematology innovations and academic achievements to medical experts from Europe and around the world at the International Symposium on Technological Innovations... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.